Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIAF 
bioAffinity Technologies, Inc. (BIAF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BIAF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.34% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.72M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 2.54 | 52 Weeks Range 0.16 - 2.26 | Updated Date 09/17/2025 |
52 Weeks Range 0.16 - 2.26 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -152.18% | Operating Margin (TTM) -198.16% |
Management Effectiveness
Return on Assets (TTM) -110.27% | Return on Equity (TTM) -1802.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7584569 | Price to Sales(TTM) 1 |
Enterprise Value 7584569 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 29568600 | Shares Floating 22864781 |
Shares Outstanding 29568600 | Shares Floating 22864781 | ||
Percent Insiders 18.89 | Percent Institutions 1.46 |
Upturn AI SWOT
bioAffinity Technologies, Inc.
Company Overview
History and Background
bioAffinity Technologies, Inc. was founded in 2014 and focuses on early cancer detection and diagnostics. The company's initial focus was on developing a non-invasive test for lung cancer.
Core Business Areas
- CyPathu00ae Lung: A proprietary platform technology used to develop diagnostic tests, including CyPathu00ae Lung for early detection of lung cancer. This is their primary focus.
- Drug Development: Researching and developing targeted cancer therapeutics based on their understanding of cancer cell metabolism.
Leadership and Structure
bioAffinity Technologies is led by Maria Zannes, the President and CEO. The company has a board of directors and a management team focused on research, development, and commercialization of its technologies.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: A non-invasive test for early detection of lung cancer using flow cytometry and proprietary biomarkers. Market share is still emerging as the test is relatively new. Competitors include companies offering liquid biopsy and imaging-based lung cancer screening tests, such as Guardant Health (GH) and Exact Sciences (EXAS).
Market Dynamics
Industry Overview
The cancer diagnostics industry is experiencing rapid growth, driven by advancements in technology and increasing demand for early and accurate cancer detection. Liquid biopsies are a key area of innovation.
Positioning
bioAffinity Technologies is positioned in the early cancer detection market, specifically targeting lung cancer with a non-invasive approach. Their competitive advantage lies in the unique biomarkers and flow cytometry technology used in CyPathu00ae Lung.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is estimated to be billions of dollars annually. bioAffinity Technologies is positioned to capture a portion of this market through the adoption of CyPathu00ae Lung by physicians and patients.
Upturn SWOT Analysis
Strengths
- Non-invasive diagnostic test
- Proprietary biomarkers
- Flow cytometry platform
- Early cancer detection focus
Weaknesses
- Limited commercialization experience
- Dependence on single product (CyPathu00ae Lung)
- Requires significant investment for growth
- Small market capitalization
Opportunities
- Expansion of CyPathu00ae platform to other cancers
- Partnerships with pharmaceutical companies
- Increasing awareness of early cancer detection benefits
- FDA approval and reimbursement
Threats
- Competition from established diagnostic companies
- Technological advancements by competitors
- Regulatory hurdles
- Funding limitations
Competitors and Market Share
Key Competitors
- GH
- EXAS
- PACB
- ILMN
Competitive Landscape
bioAffinity Technologies is a smaller player compared to established diagnostic companies. Their competitive advantage lies in their non-invasive approach and proprietary biomarkers, but they face challenges in terms of market penetration and funding.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited as bioAffinity Technologies is still in its early stages of commercialization.
Future Projections: Future growth projections depend on the successful adoption of CyPathu00ae Lung and expansion into other cancer diagnostics areas.
Recent Initiatives: Recent initiatives include efforts to increase awareness of CyPathu00ae Lung among physicians and patients, and ongoing research and development to expand the CyPathu00ae platform.
Summary
bioAffinity Technologies is a relatively new company focused on early cancer detection with a promising non-invasive lung cancer test. Its strengths lie in its proprietary technology and early detection focus, but it faces challenges related to competition, funding, and commercialization. Successful market penetration and expansion of the CyPathu00ae platform are crucial for its future growth. The company's small size also comes with a risk of high volatility.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry News and Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information is believed to be accurate but is not guaranteed. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies, Inc.
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.